Key facts
- This page summarizes Brian McKelligon's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
- 10 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 10 Jul 2025, 20:40.
Brian McKelligon - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- AKYA
- Reported as of
- 08 Jul 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jul 2025, 20:40:22 UTC
- Prior SEC filing
- 25 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian McKelligon
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brian McKelligon filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 10 Jul 2025.
Change
- Previous filing in this sequence was filed on 25 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001857447
Primary reporting owner
McKelligon Brian
- Relationship
- President and CEO, Director
- Address
- C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH
- Signature
- /s/ Brian McKelligon
- Signature date
- 10 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
transaction
Common Stock
Other
- Transaction value
- Shares
- +393,338
- Change %
- +94%
- Price
- Shares after
- 813,464
- Date
- 08 Jul 2025
- Ownership
- Direct
- Footnotes
- F1, F2
AKYA
transaction
Common Stock
Other
- Transaction value
- Shares
- +331,090
- Change %
- +41%
- Price
- Shares after
- 1,144,554
- Date
- 08 Jul 2025
- Ownership
- Direct
- Footnotes
- F1, F2
AKYA
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -196,866
- Change %
- -17%
- Price
- Shares after
- 947,688
- Date
- 08 Jul 2025
- Ownership
- Direct
- Footnotes
- F2
AKYA
transaction
Common Stock
Other
- Transaction value
- Shares
- -947,688
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -393,338
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 393,338
- Exercise price
- $0.3029
- Footnotes
- F1, F2
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -331,090
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 331,090
- Exercise price
- $0.4427
- Footnotes
- F1, F2
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -241,592
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 241,592
- Exercise price
- $16.12
- Footnotes
- F5, F6
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -160,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 160,000
- Exercise price
- $11.88
- Footnotes
- F5, F6
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -160,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 160,000
- Exercise price
- $12.30
- Footnotes
- F5, F6
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Other
- Transaction value
- $0
- Shares
- -175,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 175,000
- Exercise price
- $5.35
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Brian McKelligon is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Cashless exercise of options pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and the Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
Footnote F2
Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price less than the value of the Per Share Merger Consideration (as defined below) was automatically cashless exercised.
Footnote F3
Disposition of shares pursuant to Merger Agreement.
Footnote F4
In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
Footnote F5
Disposition of options pursuant to the Merger Agreement.
Footnote F6
Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.